Michael Okunewitch
Stock Analyst at Maxim Group
(0.54)
# 4,096
Out of 5,182 analysts
26
Total ratings
24%
Success rate
-17.43%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.14 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $0.89 | +1,023.72% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $0.87 | +586.89% | 3 | Sep 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $0.44 | +7,872.67% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.65 | +158.06% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.54 | +1,718.18% | 2 | Feb 20, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.55 | +93.55% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.70 | +135.29% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $240 | $1.43 | +16,683.22% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.90 | +566.67% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.96 | +1,151.83% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.88 | +1,176.60% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.32 | +675.86% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $1.08 | +187,400.00% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $16.57 | +50.88% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.23 | +2,490.67% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.34 | +476.04% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.69 | +14,371.78% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.14
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $0.89
Upside: +1,023.72%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $0.87
Upside: +586.89%
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $0.44
Upside: +7,872.67%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.65
Upside: +158.06%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.54
Upside: +1,718.18%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.55
Upside: +93.55%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.70
Upside: +135.29%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $240
Current: $1.43
Upside: +16,683.22%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.90
Upside: +566.67%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.96
Upside: +1,151.83%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.88
Upside: +1,176.60%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.32
Upside: +675.86%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $1.08
Upside: +187,400.00%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $16.57
Upside: +50.88%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $0.23
Upside: +2,490.67%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $4.34
Upside: +476.04%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.69
Upside: +14,371.78%